Ring Therapeutics Announces Three Presentations at the 41st Annual Meeting of the American Society for Virology (ASV)

CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) — Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today announced three upcoming presentations at the 41^st Annual Meeting of the American Society for Virology to be held from July 16-20, 2022 in Madison, Wisconsin. These presentations showcase Ring’s significant progress building out the Anellogy™ platform to engineer novel precision medicines through harnessing the unique biology of anelloviruses.

Oral Presentations:

Title: In vitro production of recombinant human anellovirus particles using synthetic viral genomes
Session Title: Replication and Gene Expression
Abstract Number: 3733463
Board number: W49-10
Presenter: Dr. Dhananjay Nawandar
Presentation Date and Time: Tuesday, July 19, 2022, 4:15 – 4:30 p.m. CST

This talk will present data from a study demonstrating an in vitro system to effectively produce anelloviruses and recapitulate tissue specific delivery in vivo. These results amplify basic understanding of anelloviruses and offer new insights into harnessing their unique biology for development of novel precision medicines.

Title: The First Structure of an Anellovirus Particle Reveals a Mechanism for Immune Evasion
Session Title: W41: Structure
Abstract Number: 3733650
Presenter: Dr. Kurt Swanson
Presentation Date and Time: Monday, July 18, 2022, 7:30 – 7:45 p.m. CST

This talk will showcase the first high resolution structure of an anellovirus and regions of the genome that are required for capsid assembly. The structure also provides a potential mechanism for anellovirus immune evasion, a hallmark of this viral family that could make them an ideal viral-based therapy.

Poster Presentations:

Title:Comprehensive profiling of antibody responses to anelloviruses within the commensal human virome using programmable phage display  
Session Title: Oncolytics, Gene Therapy and Viral Vectors
Abstract Number: 3731105
Board number: P28-1
Presenter: Dr. Harish Swaminathan
Presentation Date and Time: Monday, July 18, 2022, 8:30 – 10:00 p.m. CST

Data from this poster will illustrate that most anellovirus peptides are not associated with an antibody response in humans when compared to other known human viruses. These results further the understanding of anellovirus immune favorability.

About Ring Therapeutics
Ring Therapeutics is revolutionizing the gene therapy and nucleic acid medicine space by harnessing the most abundant and diverse member of the human commensal virome, anelloviruses. The company developed the Anellogy™ platform which focuses on anelloviruses to potentially treat a broad range of diseases. Through harnessing the unique properties of these commensal viruses, the Anellogy™ platform generates diverse vectors that exhibit both tissue-specific tropism and the potential to be re-dosed. Ring Therapeutics, founded by Flagship Pioneering in 2017, aims to develop and further expand its portfolio by leveraging its platform to unlock the full potential of gene therapy and nucleic acid medicines, enabling a variety of mechanisms that successfully deliver therapeutic cargo to unreachable organs and tissues. To learn more, visit https://www.ringtx.com/ or follow us on Twitter at @Ring_tx.

Ring Therapeutics Media:
Brittany Leigh, Ph.D.
LifeSci Communications
bleigh@lifescicomms.com
+1-813-767-7801